

Tchaikapharma High Quality Medicines Inc.
Interim statement of Financial status
as of 31 of March 2020

	31.03.2020	31.12.2019
	BGN'000	BGN'000
ASSETS		
Non-current assets		
Property, plant and equipment	26 633	26 981
Intangible assets	2 671	2 725
Assets with usable assets	368	420
Trade receivables	4 930	4 930
Total non-current assets	34 602	35 056
Current assets		
Inventories	7 839	8 763
Trade and other receivables	73 855	74 020
Current corporate income tax	-	-
Treasury shares redeemed	1	1
Cash and cash equivalents	143	40
Total current assets	81 838	82 824
Total assets	116 440	117 880
LIABILITIES		
Equity		
Share capital	82 200	82 200
Reserves	11 775	11 775
Retained earnings	4 547	2 568
Total	98 522	96 543
Non-current liabilities		
Long-term loans	1 844	2 037
Deferred tax liabilities	1 308	1 308
Retirement benefit obligations	159	159
Total non-current liabilities	3 311	3 504
Current liabilities		
Trade and other liabilities	3 944	7 095
Short-term loans	9 784	9 784
Current portion of long-term loans	654	616
Current corporate income tax		142
Other tax liabilities	225	196
Total current liabilities	14 607	17 833
Total liabilities	17 918	21 337
Total equity and liabilities	116 440	117 880

Date of preparation: 27.04.2020


Sofia

Prepared by:.....

/ P. Moneya /

Executive Director:.....

/ B. Georgiev /



Tchaikapharma High Quality Medicines Inc.
Interim statement of comprehensive income
as of 31 of March 2020

	31.03.2020	31.03.2019
	BGN'000	BGN'000
Revenue	10 848	9 332
Other income	52	
Total income	10 900	9 332
Carrying amount of goods sold	(145)	(35)
Changes in inventories of finished products and work in progress	(150)	454
Materials and services	(6 285)	(4 057)
Personnel expenses	(1 099)	(990)
Depreciation / amortisation expenses	(1 021)	(944)
Other expenses	(42)	(335)
Finance income	14	2
Finance costs	(103)	(90)
Total expenses	(8 831)	(5 995)
Profit before taxation	2 069	3 337
Corporate income tax expense	(90)	(184)
Profit/Loss for the period	1 979	3 153

Total comprehensive income for the period


Earnings per share / in BGN per 1 share /	0.02	0.04
---	------	------

Date of preparation: 27.04.2020

Sofia

Prepared by:.....
 / P. Moneva /

Executive Director:.....
 /B. Georgiev/



Tchaikapharma High Quality Medicines Inc.
Interim cash flow statement
as of 31 of March 2020

	31.03.2020	31.03.2019
	<i>BGN'000</i>	<i>BGN'000</i>
Cash flows from operating activities		
Proceeds from sale of finished products, goods and services	8 194	8 521
Payments to suppliers of materials, goods and services	(5 109)	(4 191)
Payments to personnel	(1 041)	(880)
Payments of interest and dividends	(8)	(9)
Corporate income tax payments	(232)	(309)
Other proceeds / payments	(990)	(2 504)
Net cash flows	814	628
Cash flows from investing activities		
Payments on non-current assets acquired	(559)	(350)
Net cash flows	(559)	(350)
Cash flows from financial activities		
Proceeds from loans	33	50
Payments on loans	(81)	(49)
Payment of interest, dividends	-	(61)
Payments on finance lease	(104)	(118)
Other proceeds/payments		
Net cash flows	(152)	(178)
Change in cash and cash equivalents	103	100
Cash and cash equivalents at the beginning of the period	40	250
Cash and cash equivalents at the end of the period	143	350

Date of preparation: 27.04.2020

Sofia

Prepared by:.....
 / P. Moneva /

Executive Director:.....
 /B. Georgiev /



Tchaikapharma High Quality Medicines Inc.
Interim statement on changes in equity
as of 31 of March 2020

	Registered (share) capital <i>BGN'000</i>	Revaluation reserves <i>BGN'000</i>	Other reserves <i>BGN'000</i>	Retained earnings / loss <i>BGN'000</i>	Total equity <i>BGN'000</i>
Balance as of 01.01.2019	72 200	4 124	6 477	11 199	94 000
Profit/loss for the period				2 568	2 568
Other comprehensive income		(25)			(25)
Including from tax effect of the revaluation of property, plant and equipment					(72)
Total comprehensive income		(25)		2 568	2 543
Issue of shares by the owners	10 000			(10 000)	
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves			1 199	(1 199)	
Total amount of income and expenses recognised during the period	10 000		1 199	(11 199)	
Balance as of 31.12.2019	82 200	4 099	7 676	2 568	96 543
Balance as of 01.01.2020	82 200	4 099	7 676	2 568	96 543
Profit/loss for the period				1 979	1 979
Other comprehensive income					
Total comprehensive income				1 979	1 979
Issue of shares by the owners					
Dividends accrued					
Tantiemmes accrued					
Profit transferred to reserves					
Total amount of income and expenses recognised during the period					
Balance as of 31.03.2020	82 200	4 099	7 676	4 547	98 522

Date of preparation: 27.04.2020
Sofia

Prepared by:.....

/P. Moneva/

Executive Director:.....

/B. Georgiev/